NCT02753127 2023-11-15CanStem303CSumitomo Pharma America, Inc.Phase 3 Completed1,253 enrolled 18 charts
NCT02993731 2023-11-15CanStem111PSumitomo Pharma America, Inc.Phase 3 Completed1,134 enrolled 18 charts
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA
NCT00773747 2021-04-30Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)Merck Sharp & Dohme LLCPhase 3 Completed637 enrolled 15 charts
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts